ProjectFAIR-PARK-II – Conservative iron chelation as a disease-modifying strategy in Parkinson's disease: a multicentric,…

Basic data

Acronym:
FAIR-PARK-II
Title:
Conservative iron chelation as a disease-modifying strategy in Parkinson's disease: a multicentric, parallel-group, placebo-controlled, randomized clinical trial of deferiprone
Duration:
01/05/2015 to 30/04/2020
Abstract / short description:
Parkinson’s disease (PD) is a major, chronic, non-communicable disease and the 2nd most frequent neurodegenerative disorder worldwide. Excess iron is primarily detected in the substantia nigra pars compacta, where dopaminergic neurons are exposed to high levels of oxidative stress produced by mitochondrial disorders and dopamine metabolism. Our previous preclinical, translational and pilot clinical studies demonstrated that novel iron chelation therapy with the prototypic drug
deferiprone (DFP) (i) induces neuroprotection in cell models of PD via a powerful antioxidant effect, (ii) reduces regional siderosis of the brain, (iii) reduces motor handicap via inhibition of catechol-o-methyl transferase, and (iv) slows the progression of motor handicap in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model and in early PD patients. This project now seeks to demonstrate that conservative iron chelation therapy with moderate-dose DFP (30 mg/kg/day) slows the progression of handicap in de novo PD patients while not affecting systemic parameters. The 9-month, parallel-
group, randomized, placebo-controlled, multicentre trial will be followed by a 1-month wash-out period. The primary efficacy criterion will be the change in motor and non-motor handicap scores on the Total Movement Disorders Society Unified Parkinson’s Disease Rating Scale to identify disease-modifying and symptomatic effects. The secondary efficacy criterion will be the change in score between baseline and 40 weeks (i.e. probing the disease-modifying effect only). Potential
surrogate radiological and biological biomarkers, health economics and societal impacts will be assessed. 17 national, European and international research and innovation activities will be linked with the project. The study results should prompt academic and industrial research on iron chelation as a disease-modifying treatment in neurodegenerative diseases.
Keywords:
Disease modifier
Iron chelation
Oxidative stress
neuroprotection
Neuroprotektion
clinical trial
klinische Studie
Parkinson's disease
Parkinsonerkrankung

Involved staff

Managers

Berg, Daniela
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Neurology with Focus on Neurodegenerative Disorders
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine

Funders

Brüssel, Belgium
Brüssel, Belgium
Help

will be deleted permanently. This cannot be undone.